391 related articles for article (PubMed ID: 26287983)
1. Interventions for dialysis patients with hepatitis C virus (HCV) infection.
Prabhu RA; Nair S; Pai G; Reddy NP; Suvarna D
Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD007003. PubMed ID: 26287983
[TBL] [Abstract][Full Text] [Related]
2. Interventions for dialysis patients with hepatitis C virus (HCV) infection.
Prabhu AR; Rao IR; Nagaraju SP; Rajwar E; Venkatesh BT; Nair N S; Pai G; Reddy NP; Suvarna D
Cochrane Database Syst Rev; 2023 Apr; 4(4):CD007003. PubMed ID: 37096802
[TBL] [Abstract][Full Text] [Related]
3. Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C.
Hauser G; Awad T; Brok J; Thorlund K; Štimac D; Mabrouk M; Gluud C; Gluud LL
Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD005441. PubMed ID: 24585509
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological interventions for acute hepatitis C infection: an attempted network meta-analysis.
Kalafateli M; Buzzetti E; Thorburn D; Davidson BR; Tsochatzis E; Gurusamy KS
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011644. PubMed ID: 28285495
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological interventions for acute hepatitis C infection.
Kalafateli M; Buzzetti E; Thorburn D; Davidson BR; Tsochatzis E; Gurusamy KS
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD011644. PubMed ID: 30521693
[TBL] [Abstract][Full Text] [Related]
6. Aminoadamantanes for chronic hepatitis C.
Lamers MH; Broekman M; Drenth JP; Gluud C
Cochrane Database Syst Rev; 2014 May; 2014(5):CD010125. PubMed ID: 24793264
[TBL] [Abstract][Full Text] [Related]
7. Antiviral interventions for liver transplant patients with recurrent graft infection due to hepatitis C virus.
Gurusamy KS; Tsochatzis E; Toon CD; Xirouchakis E; Burroughs AK; Davidson BR
Cochrane Database Syst Rev; 2013 Dec; 2013(12):CD006803. PubMed ID: 24307460
[TBL] [Abstract][Full Text] [Related]
8. Peginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis C.
Hauser G; Awad T; Thorlund K; Štimac D; Mabrouk M; Gluud C
Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD005642. PubMed ID: 24585451
[TBL] [Abstract][Full Text] [Related]
9. Aminoadamantanes versus other antiviral drugs for chronic hepatitis C.
Lamers MH; Broekman M; Drenth JP; Gluud C
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD011132. PubMed ID: 24937404
[TBL] [Abstract][Full Text] [Related]
10. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
11. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
[TBL] [Abstract][Full Text] [Related]
12. Antiviral prophylaxis for the prevention of chronic hepatitis C virus in patients undergoing liver transplantation.
Gurusamy KS; Tsochatzis E; Toon CD; Davidson BR; Burroughs AK
Cochrane Database Syst Rev; 2013 Dec; 2013(12):CD006573. PubMed ID: 24297303
[TBL] [Abstract][Full Text] [Related]
13. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
14. Treatment for hepatitis C virus-associated mixed cryoglobulinaemia.
Montero N; Favà A; Rodriguez E; Barrios C; Cruzado JM; Pascual J; Soler MJ
Cochrane Database Syst Rev; 2018 May; 5(5):CD011403. PubMed ID: 29734473
[TBL] [Abstract][Full Text] [Related]
15. Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C.
Koretz RL; Pleguezuelo M; Arvaniti V; Barrera Baena P; Ciria R; Gurusamy KS; Davidson BR; Burroughs AK
Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD003617. PubMed ID: 23440791
[TBL] [Abstract][Full Text] [Related]
16. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.
Hartwell D; Jones J; Baxter L; Shepherd J
Health Technol Assess; 2011 Apr; 15(17):i-xii, 1-210. PubMed ID: 21473834
[TBL] [Abstract][Full Text] [Related]
17. Nitazoxanide for chronic hepatitis C.
Nikolova K; Gluud C; Grevstad B; Jakobsen JC
Cochrane Database Syst Rev; 2014 Apr; 2014(4):CD009182. PubMed ID: 24706397
[TBL] [Abstract][Full Text] [Related]
18. Treatment for cryoglobulinemic and non-cryoglobulinemic peripheral neuropathy associated with hepatitis C virus infection.
Benstead TJ; Chalk CH; Parks NE
Cochrane Database Syst Rev; 2014 Dec; (12):CD010404. PubMed ID: 25525951
[TBL] [Abstract][Full Text] [Related]
19. Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients.
Katz LH; Goldvaser H; Gafter-Gvili A; Tur-Kaspa R
Cochrane Database Syst Rev; 2012 Sep; (9):CD008516. PubMed ID: 22972122
[TBL] [Abstract][Full Text] [Related]
20. Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease.
Saglimbene VM; Palmer SC; Ruospo M; Natale P; Craig JC; Strippoli GF
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD009904. PubMed ID: 28782299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
